MTOR and cancer: There is much clinical interest, with more than 400 registered trials (clinicaltrials.gov) using rapalogues as well as second generation inhibitors (the ATP-competitive inhibitor category of mTOR inhibitors) to treat many cancer types, such as breast, melanoma, myeloma, renal, gynecological, and brain cancers, as a mono agent or in combination.